Literature DB >> 25546094

A population-based study on combined markers for early Parkinson's disease.

Sinem Tunc1, Julia Graf, Vera Tadic, Norbert Brüggemann, Alexander Schmidt, Mohamed Al-Khaled, Simone Wolff, Eva-Juliane Vollstedt, Anne Lorwin, Jennie Hampf, Linda Piskol, Christine Klein, Johann Hagenah, Meike Kasten.   

Abstract

The prerequisite for an earlier diagnosis of Parkinson's disease (PD) are markers that are both sensitive and specific for clinically definite PD and its prediagnosic phases. Promising candidates include enlarged hyperechogenicity of the substantia nigra (SN+) on transcranial sonography (TCS) and hyposmia. However, despite good sensitivity and specificity, both markers have yet failed to yield reliable predictions. We pursue the possibility of combined use in an ongoing population-based cohort. Subjects were recruited from 10,000 inhabitants of Luebeck/Germany aged 50 to 79 years and additional PD patients from our outpatient clinic. After neurological examination, 715 subjects were grouped into clinically definite PD (n = 106), possible prediagnostic PD (ppPD; n = 73), and a control group subdivided into healthy individuals (n = 283) and controls with diseases other than PD (n = 253). Subjects underwent TCS and smell testing. Sensitivity and specificity of SN+ and hyposmia were good for PD; however, positive predictive values (PPV) of both SN+ (5.2%) and olfaction (2.5%) were low. At least one positive/both positive markers were present in 33%/1% of healthy controls, 33%/2% of diseased controls, 62%/7% of ppPD, and 94%/51% of PD. When combining SN+ and hyposmia, PPV increased to 17.6%, with a sensitivity of 51% and a specificity of 98%. Both SN+ and hyposmia offer good enrichment towards PD and ppPD, are stable against other diseases, and the combination of markers highly increases specificity. However, if the combination of SN+ and hyposmia were used as criterion for PD diagnosis, almost half of clinically definite PD and more than 90% of ppPD would have been missed.
© 2014 International Parkinson and Movement Disorder Society.

Entities:  

Keywords:  hyperechogenicity; hyposmia; population-based cohort; prediagnostic Parkinson's disease

Mesh:

Year:  2014        PMID: 25546094     DOI: 10.1002/mds.26100

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  7 in total

1.  Substantia Nigra Swelling and Dentate Nucleus T2 Hyperintensity May Be Early Magnetic Resonance Imaging Signs of β-Propeller Protein-Associated Neurodegeneration.

Authors:  Camilla Russo; Anna Ardissone; Elena Freri; Serena Gasperini; Marco Moscatelli; Giovanna Zorzi; Celeste Panteghini; Barbara Castellotti; Barbara Garavaglia; Nardo Nardocci; Luisa Chiapparini
Journal:  Mov Disord Clin Pract       Date:  2018-11-09

Review 2.  New Imaging Markers for Movement Disorders.

Authors:  Christine Ghadery; Antonio P Strafella
Journal:  Curr Neurol Neurosci Rep       Date:  2018-04-03       Impact factor: 5.081

Review 3.  Transcranial Sonography of the Substantia Nigra for the Differential Diagnosis of Parkinson's Disease and Other Movement Disorders: A Meta-Analysis.

Authors:  Yan-Liang Mei; Jing Yang; Zheng-Rong Wu; Ying Yang; Yu-Ming Xu
Journal:  Parkinsons Dis       Date:  2021-04-30

4.  Qualitative Characteristics of Depression in Parkinson's Patients and Controls.

Authors:  Cleo Kritzinger; Eva-Juliane Vollstedt; Katja Hückelheim; Anne Lorwin; Julia Graf; Sinem Tunc; Christine Klein; Meike Kasten
Journal:  Behav Neurol       Date:  2015-08-16       Impact factor: 3.342

Review 5.  Diagnostic Accuracy of Transcranial Sonography of the Substantia Nigra in Parkinson's disease: A Systematic Review and Meta-analysis.

Authors:  Dun-Hui Li; Ya-Chao He; Jun Liu; Sheng-Di Chen
Journal:  Sci Rep       Date:  2016-02-16       Impact factor: 4.379

6.  Assessment of Olfactory Function in MAPT-Associated Neurodegenerative Disease Reveals Odor-Identification Irreproducibility as a Non-Disease-Specific, General Characteristic of Olfactory Dysfunction.

Authors:  Katerina Markopoulou; Bruce A Chase; Piotr Robowski; Audrey Strongosky; Ewa Narożańska; Emilia J Sitek; Mariusz Berdynski; Maria Barcikowska; Matt C Baker; Rosa Rademakers; Jarosław Sławek; Christine Klein; Katja Hückelheim; Meike Kasten; Zbigniew K Wszolek
Journal:  PLoS One       Date:  2016-11-17       Impact factor: 3.240

7.  Diagnostic Value of Combined Acute Levodopa Challenge and Olfactory Testing to Predict Parkinson's Disease.

Authors:  Cinthia Terroba Chambi; Malco Rossi; Andrea Bril; Patricio Millar Vernetti; Daniel Cerquetti; Angel Cammarota; Marcelo Merello
Journal:  Mov Disord Clin Pract       Date:  2017-09-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.